COVID-19 patients have a high incidence of thrombosis, and thromboembolic complications
are associated with severe COVID-19 and high mortality. COVID-19 disease is associated …

Three and a half years after the pandemic outbreak, now that WHO has formally declared
that the emergency is over, COVID-19 is still a significant global issue. Here, we focus on …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Background: Excessive daytime sleepiness (EDS) is common among patients with
obstructive sleep apnea (OSA). The comparative effectiveness of pharmacologic agents is …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

Background Remdesivir is considered to be a specific drug for treating coronavirus disease
2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir …

Convergence of the two pandemics: metabolic syndrome and COVID-19 over last two years
has posed unprecedented challenges to individuals as well as healthcare systems …

In 2022, three antiviral drugs—molnupiravir, remdesivir and nirmatrelvir/ritonavir—were
introduced for treatment of mild-to-moderate COVID-19 in high-risk patients. The aim of this …

The Omicron, the latest variant of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), was first detected in November 2021 in Botswana, South Africa. Compared to other …

Antiviral treatment reduces the severity and mortality of SARS-CoV-2 infection; however, its
effectiveness against long COVID-19 is unclear. This study aimed to evaluate the …